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Background/Aims: Bicarbonate-containing alginate formula-
tions are reported to be effective for controlling reflux symp-
toms. However, the efficacy of Lamina G alginate without gas 
production has not been reported. The aim is to evaluate 
the efficacy of a non-bicarbonate alginate in individuals with 
reflux symptoms without reflux esophagitis. Methods: Par-
ticipants who had experienced heartburn or regurgitation for 
7 consecutive days were randomized to one of the following 
treatment groups: proton pump inhibitors (PPI) plus alginate 
(combination) or PPI plus placebo (PPI only). In addition, as 
a reference group, patients received placebo plus alginate 
(alginate only). The primary endpoint compared the percent-
age of patients with complete resolution of symptoms for 
the final 7 days of the treatment. Secondary endpoints com-
pared changes in symptom score, symptom-free days during 
the treatment period, the Reflux Disease Questionnaire, Pa-
tient Assessment of Upper Gastrointestinal Disorders (PAGI)-
Quality of Life and PAGI-Symptoms Severity Index scores, the 
investigator’s assessment of symptoms, and incidence of ad-
verse events. Results: Complete resolution of heartburn or 
regurgitation was not significantly different between the com-
bination and PPI only groups (58.7% vs 57.5%, p=0.903). 
The secondary endpoints were not significantly different 
between the two groups. Complete resolution of heartburn 
or regurgitation, did not differ between the alginate only 
reference group and the PPI only group (75.0% vs 57.5%, 
p=0.146). Conclusions: The addition of non-bicarbonate al-
ginate to PPI was no more effective than PPI alone in control-
ling reflux symptoms.  (Gut Liver 2019;13:642-648 )
Key Words: Gastroesophageal reflux; Proton pump inhibitors; 
Alginates; Bicarbonates (CRIS KCT0002297) 
INTRODUCTION
Gastroesophageal reflux disease (GERD) is a representative 
gastrointestinal disease with a multifactorial pathophysiology.1 
Proton pump inhibitors (PPIs) have previously been shown to be 
the most effective treatment for GERD. However, other medica-
tions based on pathophysiology have also been investigated as 
treatments for GERD. One of the pathophysiologies typical of 
GERD is the presence of an acid pocket. The acid pocket is an 
area containing unbuffered, highly acidic gastric secretions that 
are located in the proximal stomach after meals. This zone acts 
as a reservoir from which acid can enter the esophagus when 
the esophagogastric junction opens.2 Thus, the acid pocket rep-
resents an effective target for the treatment of GERD.2 Alginate-
based formulations act primarily on these acid pockets by 
forming a physical barrier. That is, when contacting with gastric 
acid, alginate rapidly forms a gel “raft” of near-neutral pH as a 
protective mechanical barrier above the acidic gastric contents.3 
Several studies have investigated the efficacy of sodium algi-
nate, in particular the branded antacid product Gaviscon, in the 
alleviation of symptoms associated with GERD.1,3-6
Most alginate formulations, including Gaviscon, consist of 
three chemical components: sodium alginate; sodium bicarbon-
ate, which reacts with stomach acid to yield carbon dioxide; 
and calcium carbonate, which reacts with stomach acid to yield 
free calcium ions.7 This combination of components results in 
the production of an alginate antacid raft with gas produc-
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tion.7-9 Although pure sodium alginate without gas production 
can act as a gel raft of matrix-forming polymers,8,9 there is no 
evidence that pure sodium alginate can be effective in control-
ling reflux symptoms on its own. Thus, the aim of study was to 
evaluate the efficacy of a non-bicarbonate alginate (Lamina G; 
Taejoon Pharm Co, Seoul, Korea) in reducing reflux symptoms 
in individuals with reflux symptoms without evidence of reflux 
esophagitis in endoscopy. 
MATERIALS AND METHODS
1. Study design 
A randomized, double-blind, parallel-group, comparative 
study was conducted over 4 weeks in the outpatient Gas-
troenterology Clinics of Severance and Gangnam Severance 
Hospitals, Seoul, Korea, between July 2014 and August 2016. 
The study was conducted involving patients with heartburn or 
regurgitation symptoms without evidence of reflux esophagitis 
in a screening endoscopy. 
Patients received one of the following treatments for 4 weeks: 
20 mg omeprazole once daily plus placebo (PPI only group) 
or 20 mg omeprazole plus 20 mL sodium alginate suspension 
(Lamina G, Taejoon Pharm Co.) three times daily (t.i.d.) (50 mg/
mL) (combination group). A reference group of patients received 
placebo plus 20 mL sodium alginate suspension t.i.d. (50 mg/
mL) (alginate only group).
The primary aim was to assess the percentage of patients with 
complete resolution of heartburn or regurgitation symptoms 
over the final 7 days of the 4-week treatment. The secondary 
aim was to assess symptom-free days or overnight symptom-
free days over the 4-week treatment period. Any change from 
the baseline Reflux Disease Questionnaire (RDQ),10,11 Patient 
Assessment of Upper Gastrointestinal Disorders-Quality of Life 
(PAGI-QOL)12 and PAGI-Symptoms Severity Index (PAGI-SYM)13 
scores, as well as the clinical investigator’s assessment for 
symptoms, were also assessed. The safety profile of subjects was 
investigated based on the incidences of adverse events (AEs). 
Subjects were enrolled to participate in the study during 
1-week screening and 4-week treatment period. After the 
initial screening period, subjects who met the inclusion criteria 
without exclusion criteria were randomized and assigned to 
treatment groups. Subjects received the study drug on day 1 
and returned to scheduled clinic appointments at week 4 for 
assessment of GERD symptoms based on patient diaries; RDQ, 
PAGI-QOL, and PAGI-SYM scores; concomitant medication use; 
and the incidences of AEs. The remaining study medication was 
collected at week 4. All subjects had a physical examination 
with blood tests at both the initial appointment and the end 
of week 4. Female subjects had pregnancy tests performed 
at the initial and the week 4 appointments, and results were 
documented. The protocol was approved by the institutional 
review boards of each institution. Written informed consents 
were obtained. The study was registered at cris.nih.go.kr (No. 
KCT0002297). 
2. Patients 
Subjects who met the inclusion criteria were eligible to par-
ticipate in the present study: males and females of Korean eth-
nicity aged 20 to 80 years old; outpatients who had a history 
of episodes of heartburn or regurgitation symptoms for at least 
3 months without evidence of reflux esophagitis in a screen-
ing endoscopy; symptoms of heartburn or regurgitation during 
the 1-week screening period (either ≥4 days of mild symptom 
or ≥ 2days of moderate to severe symptoms); and agreement to 
sign the informed consent form. The severity of symptoms was 
documented on a 4-point scale: 0=none (no symptoms), 1=mild 
(easily tolerated symptoms; symptoms were minimal and did 
not disturb normal activities), 2=moderate (symptoms disturbed 
normal activities), and 3=severe (symptoms markedly disturbed 
normal activities).1
Patients were ineligible to participate in the study when one 
or more of the following conditions were present: erosive reflux 
disease, Barrett’s esophagus or esophageal stricture; active or 
healing gastroduodenal ulcer with the exception of evidence 
of a healed ulcer with scarring; history of esophageal, gastric, 
or duodenal surgery; any kind of malignant disease; ischemic 
heart disease by electrocardiogram; pregnant or nursing moth-
ers; allergic history to the study drugs; alcohol or drug abuse; 
clinically significant liver problems (AST/SGOT, ALT/SGPT >2.5 
upper limits of normal); clinically significant renal problems 
(serum creatinine >1.5 mg/dL); using a PPI within 2 weeks be-
fore screening, or use of prokinetics, H2-blocker, or antacids 
within 3 days before screening; participation in another clinical 
study within 4 weeks before screening; and any condition that 
an investigator considered to be inappropriate for the study (for 
example, reflux-like symptoms according to other organic dis-
ease).
3. Treatment allocation
Treatment allocation was done according to a computer-gen-
erated randomization code list provided by a statistician. Ran-
domization was performed at the investigational sites. Partici-
pants were randomly assigned to receive one of the treatments 
for 4 weeks with a 2:2:1 ratio (PPI only group: combination 
group: alginate only group). The prescribed treatment schedule 
included a 20 mg omeprazole capsule before breakfast and 20 
mL (50 mg/mL) Lamina G t.i.d. before meals. All processes were 
performed using a double-blind approach. The compliance with 
the medication was checked by counting the residual study 
drugs during every visit. If the final compliance rate was less 
than 80%, the data of the patient was excluded in the per pro-
tocol analysis.
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4. Efficacy evaluation
The primary efficacy endpoint was measured as the percent-
age of subjects with complete resolution of reflux symptoms 
over the final 7 days of the treatment based on the patient di-
ary. 
The secondary efficacy endpoint was evaluated by the follow-
ing: (1) changes of symptom score (patient diary) from the base-
line, (2) symptom-free days during the 4-week treatment period 
(%, patient diary), (3) overnight symptom-free days during the 
4-week treatment period (%, patient diary), changes from the 
baseline (4) RDQ, (5) PAGI-QOL, (6) PAGI-SYM scores, and (7) 
the clinical investigator’s assessment of symptom improvement. 
Safety was assessed by vital signs and physical examinations, 
including blood tests, at both the initial appointment and the 
end of week 4. All AEs were recorded including the onset date, 
end date, severity, the relationship with study drugs, the treat-
ment modification, and outcomes. 
5. Sample size calculation
Sample size calculation was based on the assumption the 
combination group had a higher adequate heartburn-relief rate 
than the PPI only group (56.7% vs 25.7%, respectively).4 The 
following formula was used to calculate the sample size for each 
group: 
n=(1.96+0.84)2×(25.7×74.3+56.7×43.3)/(25.7–56.7)2
More than 36 patients were required per group for a 5% sig-
nificance level and a statistical power of 80%. Therefore, we de-
cided to enroll at least 48 patients in each group (PPI only and 
combination group) with an estimated drop-out rate of 25% due 
to follow up loss and protocol violations. Given the 2:2:1 group 
ratio used in this study, 24 patients were recruited for the refer-
ence group. 
6. Statistical analysis
Baseline characteristics were summarized according to treat-
ment groups. Quantitative data were reported as means and 
standard deviation, whereas categorical data were expressed as 
proportions. The chi-square and Fisher exact tests were used to 
evaluate the associations among various categorical variables, 
and the t-test or Wilcoxon rank sum tests was used to compare 
non-categorical variables. All analyses were performed us-
ing SAS 9.2 (SAS institute Inc., Cary, NC, USA), and a p-value 
<0.05 was considered to indicate statistical significance.
RESULTS
1. Participant demographics and baseline characteristics 
One hundred twenty patients were enrolled and randomized 
(Fig. 1). Two patients did not take any study drug resulting in a 
population of 118 patients. All subjects (46 in the combination 
group and 47 in the PPI only group) reported some efficacy data 
and the outcomes were analyzed (intention-to-treat population). 
The demographic and baseline characteristics among the study 
groups, including the reference group, are summarized in Table 1.
2. Primary efficacy analysis 
The primary endpoint compared the percentage of patients 
144 Screened
24 Screen failure
120 Randomized
2 Randomized
but not treated
24 Alginate alone
(reference group)
46 PPI+Alginate
combination group
48 PPI alone group
24 Alginate reference group 46 Combination group 47 PPI alone group
1 Withdrawn
20 Completed 42 Completed 38 Completed
3
1
Taking of prohibited
concomitant drug
Compliance rate less
than 80%
2 Taking of prohibited
concomitant drug
1 Compliance rate less
than 80%
1 Study visit out of
timeframe
2 Taking of prohibited
concomitant drug
4 Compliance rate less
than 80%
3 Study visit out of
timeframe
Fig. 1. Patient flowchart.
PPI, proton pump inhibitor.
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with complete resolution of symptoms over the final 7 days of 
treatment (Table 2). Complete resolution of heartburn or regur-
gitation was not significantly different between the combination 
and PPI only groups (58.7% vs 57.5%, p=0.903). In addition, 
complete resolution of heartburn or regurgitation was also not 
significantly different between the PPI only and the alginate 
only groups (57.5% vs 75.0%, p=0.146).
3. Secondary efficacy analysis
The symptom scores were significantly lower than the base-
line in all study groups, including the reference group (Table 
3). However, the changes in symptom scores from baseline 
were not significantly different between the combination and 
PPI only groups (–10.2±8.4 vs –10.4±8.4, p=0.951). There was 
also no significant difference between the alginate only refer-
ence group and the PPI only group (–10.2±9.2 vs –10.4±8.4, 
p=0.879).
Other factors, including symptom-free days during treatment 
period (Table 4), the change in RDQ, PAGI-QOL, and PAGI-SYM 
scores (Table 5), and the clinical investigator’s assessment of 
symptoms (data not shown), were not significantly different be-
tween the combination and PPI only groups. There was also no 
significant difference when comparing all secondary endpoints 
of the alginate only reference group with those of the PPI only 
group. 
The incidence of AEs was investigated. Seven patients (14.9%) 
in the combination group, 12 patients (25.5%) in the PPI only 
group, and six patients (25.0%) in the alginate only group re-
ported mild to moderate AEs. However, no severe AEs were re-
ported in any of the treatment groups, and the incidence of AEs 
Table 1. Baseline Patient Characteristics
Characteristic PPI+alginate PPI Alginate p-value* p-value†
Male sex 8 (17.4) 11 (23.4) 4 (16.7) 0.472 0.511
Age, yr 49.2±12.1 47.7±12.1 50.4±10.8 0.583 0.361
Weight, kg 57.3±8.2 59.1±10.4 56.5±8.8 0.410 0.240
BMI, kg/m2 22.2±2.3 22.3±2.8 22.0±3.2 0.892 0.733
Heartburn
   Day per week 6.4±1.4 5.7±2.3 6.2±1.8 0.460 0.422
   Sum of score‡ 8.7±4.0 7.8±4.7 8.0±3.8 0.341 0.615
Acid regurgitation
   Day per week 6.3±1.7 6.0±2.1 5.9±2.0 0.593 0.538
   Sum of score‡ 8.8±4.3 7.7±4.3 7.4±3.4 0.199 0.875
Data are presented as number (%) or mean±SD.
PPI, proton pump inhibitor; BMI, body mass index.
*p-value (PPI+alginate vs PPI); †p-value (PPI vs alginate); ‡Score: none (0), mild (1), moderate (2), and severe (3).
Table 2. Percentage of the Patients with Complete Resolution of Symptoms for the Last 7 Consecutive Days
PPI+alginate PPI Alginate p-value* p-value†
Heartburn 21 (45.7) 20 (47.6) 13 (54.2) 0.853 0.609
Regurgitation 20 (45.5) 23 (52.3) 10 (45.5) 0.522 0.602
Heartburn or regurgitation 27 (58.7) 27 (57.5) 18 (75.0) 0.903 0.146
Data are presented as number (%).
PPI, proton pump inhibitor.
*p-value (PPI+alginate vs PPI); †p-value (PPI vs alginate).
Table 3. Changes in Symptom Score from Baseline
PPI+alginate PPI Alginate p-value* p-value†
Heartburn & regurgitation‡ 7.3±8.7 5.2±6.6 5.2±7.3 0.218 0.639
Changes of symptom score§ –10.2±8.4 –10.4±8.4 –10.2±9.2 0.951 0.879
p-value (intragroup) <0.0001 <0.0001 <0.0001
Data are presented as mean±SD.
PPI, proton pump inhibitor.
*p-value (PPI+alginate vs PPI); †p-value (PPI vs alginate); ‡Sum of symptom scores for the last 7 consecutive days; §From the sum of symptom 
scores at baseline. 
646  Gut and Liver, Vol. 13, No. 6, November 2019
was not significantly different among treatment groups. One 
patient in the PPI only group withdrew from the study treat-
ment due to an AE of mild dyspepsia. 
DISCUSSION
This study showed that the addition of a non-bicarbonate al-
ginate (Lamina G) together with PPI was not more effective than 
a PPI regime on its own in the alleviation of reflux symptoms. 
However, when analyzing the data from the reference group, a 
pure alginate regimen may be as effective as a PPI regimen on 
its own in reducing reflux symptoms without evidence of reflux 
esophagitis in endoscopy. 
Since a longer and more robust treatment is necessary for 
successful mucosal healing,14-17 initial PPI treatment is often 
recommended for more than 8 weeks in erosive reflux disease 
patients.14-17 Conversely, the treatment goal of nonerosive re-
flux disease (NERD) patients is only symptom relief. Previous 
studies have reported symptom relief in GERD patients without 
evidence of reflux esophagitis following 4 weeks of PPI treat-
ment.17-20 Furthermore, patients with NERD are not treated well 
despite taking high-dose PPI. Considering the risks of long-term 
PPI use, the shortest duration or the lowest dose of PPI is an 
important factor when managing GERD treatment.21,22 Effective 
alternatives to PPI for symptom relief in GERD patients with-
out evidence of reflux esophagitis would thus also be clinically 
valuable. Although further evidence is required to validate our 
data, the present study showed that monotherapy with an algi-
nate alone can provide reflux symptom reduction in GERD pa-
tients without evidence of reflux esophagitis comparable to that 
with PPI treatment alone. 
Pathophysiological mechanisms of GERD are categorized into 
factors that promote the occurrence of reflux and/or increase 
the perception of reflux.23 The latter can be of particular impor-
tance in patients without diagnosed esophagitis.23 An alginate 
acts on both mechanisms; the acid pocket as the factor promot-
ing the occurrence of reflux, and mucosal integrity as the factor 
increasing the perception of reflux.
A floating drug-delivery system can act as a physical bar-
rier against the acid pocket. Floating drug-delivery systems are 
divided into effervescent and noneffervescent systems.8,24 The 
effervescent system includes gas-generating treatments such as 
the Gaviscon formulation, whereas the noneffervescent system 
includes matrix-forming polymers such as sodium alginate used 
Table 4. Symptom-Free Days during the 28-Day Treatment Period
PPI+alginate PPI Alginate p-value* p-value†
Heartburn-free days, % 44.7±34.7 57.4±37.4 56.6±37.9 0.102 0.937
Regurgitation-free days, % 50.8±38.0 57.8±35.3 56.2±34.1 0.317 0.733
Overnight symptom-free days, % 74.8±33.1 83.7±21.3 80.7±28.1 0.454 0.915
Data are presented as mean±SD.
PPI, proton pump inhibitor.
*p-value (PPI+alginate vs PPI); †p-value (PPI vs alginate).
Table 5. RDQ, PAGI-QOL, and PAGI-SYM Survey Score Change
PPI+alginate PPI Alginate p-value* p-value†
RDQ
   Baseline 17.5±5.4 15.5±4.9 15.8±4.7 0.046 0.562
   28-day 9.3±8.5 6.0±5.9 5.9±5.7 0.074 0.955
   Change from baseline –8.2±7.6 –9.5±5.7 –9.8±7.2 0.421 0.747
PAGI-QOL
   Baseline 35.5±26.3 29.9±25.9 34.1±25.4 0.240 0.375
   28-day 17.0±20.3 12.3±17.0 12.6±16.6 0.212 0.750
   Change from baseline –18.4±21.5 –17.7±20.8 –21.5±20.5 0.969 0.193
PAGI-SYM
   Baseline 32.3±21.0 23.2±16.3 27.2±17.6 0.036 0.371
   28-day 16.5±17.1 10.8±12.9 11.8±13.2 0.047 0.956
   Change from baseline –15.9±17.3 –12.4±11.9 –15.4±14.7 0.562 0.555
Data are presented as mean±SD.
RDQ, Reflux Disease Questionnaire; PAGI-QOL, Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life; PAGI-SYM, PAGI-Symp-
toms Severity Index; PPI, proton pump inhibitor.
*p-value (PPI+alginate vs PPI); †p-value (PPI vs alginate).
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in the present study.8,24 To the best of our knowledge, no study 
has evaluated the effectiveness of noneffervescent, pure sodium 
alginate treatment in GERD patients. Our study is the first to in-
vestigate the efficacy of pure sodium alginate in GERD patients. 
According to a previous report, raft formation was observed by 
endoscopy after 28 seconds of infusion with Lamina G.24 Con-
sidering this rapid raft formation, sodium alginate could be an 
effective therapy for rapid symptom relief in GERD patients. 
Microscopic impairment of the esophageal epithelium can 
be a pathophysiological factor of symptoms in GERD patients, 
explained as a relationship between impaired mucosal integrity 
and sensitivity to acid.23,25 Recent studies measuring mucosal 
integrity by baseline esophageal impedance (mean noctur-
nal baseline impedance, MNBI)23,26 highlight an important 
tool in predicting experimental sensitivity to acid. MNBI was 
significantly lower in NERD patients than in healthy control 
patients.26,27 According to the previous studies, the esophageal 
mucosa in NERD patients showed distinct vulnerability when 
exposed to acids/weak acids, and vulnerable mucosa could be 
protected by an alginate-containing topical solution.28,29 That 
is, alginates have bioadhesive potential, and can be prescribed 
as a topical treatment to maintain esophageal mucosal integrity 
against acid reflux from the stomach.28-30
Based on our findings here, pure sodium alginate may be 
an effective monotherapy for symptom relief in GERD patients 
without evidence of reflux esophagitis. However, we designed 
the study to compare a PPI treatment with a combination treat-
ment (PPI and alginate), not with alginate only group. The algi-
nate only group was designed arbitrarily as a reference group to 
show whether alginate monotherapy could be effective in GERD 
patients without evidence of reflux esophagitis. Thus, further 
study is required to validate the efficacy of pure sodium alginate 
in GERD patients without evidence of reflux esophagitis.
Our study is the first to evaluate the effect of pure sodium 
alginate in controlling reflux symptoms. However, it has sev-
eral limitations. First, the study participants were selected to 
have reflux symptoms without evidence of reflux esophagitis in 
endoscopy. Ambulatory pH monitoring was not performed to 
exclude functional heartburn or hypersensitive esophagus. This 
may be one of the reasons not to show additional effect of pure 
sodium alginate to PPI in the study. Second, rescue medications 
for uncontrolled symptoms were not planned in the study. Thus, 
the possibility of self-rescue medication was not fully excluded. 
Third, the alginate only group was designed arbitrarily as a 
reference group without statistical evidence. Thus, further study 
is required to evaluate the efficacy of pure sodium alginate in 
GERD patients without evidence of reflux esophagitis. Fourth, 
psychiatric disorders such as depression and anxiety may play a 
role in GERD symptom manifestation. However, the use of psy-
chiatric medication or a history of psychiatric disorder was not 
evaluated. 
In conclusion, the addition of pure sodium alginate to PPI 
was no more effective than PPI alone in GERD patients with-
out evidence of reflux esophagitis. Further study designed to 
compare pure sodium alginate with PPI only is necessary in the 
future. 
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